글로벌 타디브 디스키네시아 치료 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 타디브 디스키네시아 치료 시장

타디브 디스키네시아 치료 시장은 2021년에서 2028년까지의 예측 기간 동안 4.22%의 시장 성장을 목격할 것으로 예상됩니다. 타디브 디스키네시아 치료 시장에 대한 Data Bridge Market Research 보고서는 예측 기간 동안 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다. 환자에게 치료를 제공하기 위한 규제 당국의 특별 지정이 증가함에 따라 타디브 디스키네시아 치료 시장 성장이 가속화되고 있습니다.

타디브 디스키네시아(TD)는 정신분열증과 기타 신경이완 장애를 앓고 있는 환자가 항정신병 약물을 장기간 사용함으로써 유발되는 장애로 알려져 있습니다. 입술, 안구, 혀와 같은 신체 부위의 비자발적이고 통제되지 않은 움직임으로 간주됩니다.

예측 기간 동안 타디브 디스키네시아 치료 시장 성장을 촉진할 것으로 예상되는 주요 요인은 전 세계적으로 정신병 또는 신경 장애의 유병률 증가 입니다. 또한, 질병 특정적 새로운 치료 에 대한 수요 증가는 타디브 디스키네시아 치료 시장 성장을 더욱 촉진할 것으로 예상됩니다. 반면, 많은 제약 회사의 표적 치료 연구 및 개발에 대한 운영 수익 전망이 부족하여 타임라인 기간 동안 타디브 디스키네시아 치료 시장 성장을 더욱 방해할 것으로 예상됩니다.

또한, 새로운 개입을 발전시키기 위한 연구자에 대한 재정 지원의 증가는 향후 몇 년 동안 타디브 디스키네시아 치료 시장의 성장에 대한 잠재적 기회를 더욱 제공할 것입니다. 그러나 일부 선진 국가의 의료 예산 감소는 가까운 미래에 타디브 디스키네시아 치료 시장의 성장에 더욱 도전이 될 수 있습니다.

The tardive dyskinesia treatment market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the tardive dyskinesia treatment market scenario, contact Data bridge market research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Tardive Dyskinesia Treatment Market Scope and Market Size

The tardive dyskinesia treatment market is segmented on the basis of treatment, drugs, route of administration, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of treatment, the tardive dyskinesia treatment market is segmented into medication and surgery.
• On the basis of drugs, the tardive dyskinesia treatment market is segmented into approved drugs and off-label drugs.
• On the basis of route of administration, the tardive dyskinesia treatment market is segmented into oral and injectable.
• On the basis of distribution channels, the tardive dyskinesia treatment market is segmented into hospital pharmacies, retail pharmacies, and others.

Tardive Dyskinesia Treatment Market Country Level Analysis

The tardive dyskinesia treatment market is analyzed, and market size information is provided by country, treatment, drugs, route of administration, and distribution channel as referenced above.

The countries covered in the tardive dyskinesia treatment market report are the U.S., Canada, and Mexico in North America, Peru, Brazil, Argentina, and the rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA).

North America dominates the tardive dyskinesia treatment market due to the rise in the incidence of schizophrenia. Furthermore, the growth of the health alertness and the increase in the research and development investment will further boost the growth of the tardive dyskinesia treatment market in the region during the forecast period. Asia-Pacific is projected to observe a significant amount of growth in the tardive dyskinesia treatment market due to a rise in health awareness. Moreover, the increase in the number of schizophrenic, bipolar, and other neuroleptic disorder patients is further anticipated to propel the growth of the tardive dyskinesia treatment market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The tardive dyskinesia treatment market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to the market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Tardive Dyskinesia Treatment Market Share Analysis

The tardive dyskinesia treatment market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the tardive dyskinesia treatment market.

타디브 디스키네시아 치료 시장 보고서에 포함된 주요 기업으로는 Teva Pharmaceutical Industries Ltd, Neurocrine Biosciences, Inc, Medicure Inc, Mylan NV, Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Bionpharma, Hetero, Bausch Health, Sanofi, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Lupin Pharmaceuticals Inc., Lilly, Novartis AG, AbbVie Inc, Pfizer Inc, Bayer AG, Baxter, Merck KGaA, Amgen Inc 등이 있으며, 국내 및 글로벌 기업도 있습니다. 타디브 디스키네시아 치료 시장 점유율 데이터는 글로벌, 북미, 남미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA)에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-46634